{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:26:43Z","timestamp":1786591603745,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"DOI":"10.7759\/cureus.101371","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:41:00Z","timestamp":1768236060000},"source":"Crossref","is-referenced-by-count":3,"title":["Nimesulide-Associated Generalized Bullous Fixed Drug Eruption: A Rare Pharmacovigilance Case Report"],"prefix":"10.7759","author":[{"given":"Mannu","family":"Marshal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh K","family":"Badyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061583","article-title":"Nimesulide-induced fixed drug eruption followed by etoricoxib-induced fixed drug eruption: an unusual case report and review of the literature","volume":"13","author":"Makris M","year":"2024","unstructured":"Makris M, Papapostolou N, Koumprentziotis IA, Pappa G, Katoulis AC. Nimesulide-induced fixed drug eruption followed by etoricoxib-induced fixed drug eruption: an unusual case report and review of the literature. J Clin Med. 2024, 13:10.3390\/jcm13061583","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57090925","article-title":"A review of fixed drug eruption with a special focus on generalized bullous fixed drug eruption","volume":"57","author":"Anderson HJ","year":"2021","unstructured":"Anderson HJ, Lee JB. A review of fixed drug eruption with a special focus on generalized bullous fixed drug eruption. Medicina (Kaunas). 2021, 57:10.3390\/medicina57090925","journal-title":"Medicina (Kaunas)"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.5070\/D3237035734","article-title":"Generalized bullous fixed drug eruption imitating toxic epidermal necrolysis: a case report and literature review","volume":"23","author":"Mitre V","year":"2017","unstructured":"Mitre V, Applebaum DS, Albahrani Y, Hsu S. Generalized bullous fixed drug eruption imitating toxic epidermal necrolysis: a case report and literature review. Dermatol Online J. 2017, 23:","journal-title":"Dermatol Online J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.25259\/IJPP_497_2023","article-title":"Stevens-Johnson syndrome: an adverse drug reaction with various drugs","volume":"69","author":"Joseph G","year":"2025","unstructured":"Joseph G, Bhatti N, Badyal DK, Kaur P. Stevens-Johnson syndrome: an adverse drug reaction with various drugs. Indian J Physiol Pharmacol. 2025, 69:1-4. 10.25259\/IJPP_497_2023","journal-title":"Indian J Physiol Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/ds.DS-D-24-00275","article-title":"Fixed drug eruption-A retrospective review of 146 patients in a tertiary hospital in Southern Taiwan","volume":"43","author":"Yeh JW","year":"2025","unstructured":"Yeh JW, Liu WT. Fixed drug eruption-A retrospective review of 146 patients in a tertiary hospital in Southern Taiwan. Dermatol Sin. 2025, 43:124-8. 10.4103\/ds.DS-D-24-00275","journal-title":"Dermatol Sin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.09.024","article-title":"Fixed drug eruption and generalized bullous fixed drug eruption: Insights from an analysis of the FDA Adverse Event Reporting System","volume":"13","author":"Shrestha P","year":"2025","unstructured":"Shrestha P, Stone CA Jr, Phillips EJ. Fixed drug eruption and generalized bullous fixed drug eruption: Insights from an analysis of the FDA Adverse Event Reporting System. J Allergy Clin Immunol Pract. 2025, 13:236-237.e1. 10.1016\/j.jaip.2024.09.024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26061513","article-title":"lubility, permeability, anti-inflammatory action and in vivo pharmacokinetic properties of several mechanochemically obtained pharmaceutical solid dispersions of nimesulide","volume":"26","author":"Wei W","year":"2021","unstructured":"Wei W, Evseenko VI, Khvostov MV, et al.. lubility, permeability, anti-inflammatory action and in vivo pharmacokinetic properties of several mechanochemically obtained pharmaceutical solid dispersions of nimesulide. Molecules. 2021, 26:10.3390\/molecules26061513","journal-title":"Molecules"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.59556\/japi.73.0870","article-title":"Nimesulide: critical appraisal of safety and efficacy in acute pain","volume":"73","author":"Tiwaskar M","year":"2025","unstructured":"Tiwaskar M, Charde S, Balankhe N, et al.. Nimesulide: critical appraisal of safety and efficacy in acute pain. J Assoc Physicians India. 2025, 73:e22-8. 10.59556\/japi.73.0870","journal-title":"J Assoc Physicians India"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.05.008","article-title":"Simultaneous determination of nimesulide and its four possible metabolites in human plasma by LC-MS\/MS and its application in a study of pharmacokinetics","volume":"1027","author":"Sun X","year":"2016","unstructured":"Sun X, Xue KL, Jiao XY, Chen Q, Xu L, Zheng H, Ding YF. Simultaneous determination of nimesulide and its four possible metabolites in human plasma by LC-MS\/MS and its application in a study of pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci. 2016, 1027:139-48. 10.1016\/j.jchromb.2016.05.008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref10","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD);"},{"key":"ref11","unstructured":"VigiAccess. WHO global database of individual case safety reports. (2015). Accessed. December 2, 2025: https:\/\/www.vigiaccess.org\/."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","article-title":"Preventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"Hartwig SC","year":"1992","unstructured":"Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992, 49:2229-32.","journal-title":"Am J Hosp Pharm"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed M","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S, et al.. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004, 329:15-9. 10.1136\/bmj.329.7456.15","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65390","article-title":"Sodium valproate-induced hyperammonemia: a case series in a tertiary care hospital","volume":"16","author":"Abhilasha P","year":"2024","unstructured":"Abhilasha P, Bhatti N, Joseph G, Badyal DK. Sodium valproate-induced hyperammonemia: a case series in a tertiary care hospital. Cureus. 2024, 16:e65390. 10.7759\/cureus.65390","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/NJPT.NJPT_24_25","article-title":"Ondansetron-induced dystonia: an uncommon case report","volume":"3","author":"Kaur M","year":"2025","unstructured":"Kaur M, Mongia AK, Joseph G, Bhatti N, Badyal DK. Ondansetron-induced dystonia: an uncommon case report. Natl J Pharmacol Ther. 2025, 3:150-2. 10.4103\/NJPT.NJPT_24_25","journal-title":"Natl J Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28299","article-title":"Fixed drug eruption: an underrecognized cutaneous manifestation of a drug reaction in the primary care setting","volume":"14","author":"Shaker G","year":"2022","unstructured":"Shaker G, Mehendale T, De La Rosa C. Fixed drug eruption: an underrecognized cutaneous manifestation of a drug reaction in the primary care setting. Cureus. 2022, 14:e28299. 10.7759\/cureus.28299","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1125754","article-title":"Case report: generalized bullous fixed drug eruption mimicking epidermal necrolysis","volume":"10","author":"Paulmann M","year":"2023","unstructured":"Paulmann M, Reinkemeier F, Lehnhardt M, Mockenhaupt M. Case report: generalized bullous fixed drug eruption mimicking epidermal necrolysis. Front Med (Lausanne). 2023, 10:1125754. 10.3389\/fmed.2023.1125754","journal-title":"Front Med (Lausanne)"},{"key":"ref19","article-title":"Cutaneous adverse drug reactions and their impact on the quality of life of patients: a study at a tertiary care centre","volume":"19","author":"Shivani","year":"2025","unstructured":"Shivani, Sinha R, Arya AK, Jaykar KC, Pallavi UK. Cutaneous adverse drug reactions and their impact on the quality of life of patients: a study at a tertiary care centre. IMC J Med Sci. 2025, 19:006.","journal-title":"IMC J Med Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1157\/13080933","article-title":"Nimesulide-induced fixed drug eruption","volume":"33","author":"Malheiro D","year":"2005","unstructured":"Malheiro D, Cadinha S, Rodrigues J, Vaz M, Castel-Branco MG. Nimesulide-induced fixed drug eruption. Allergol Immunopathol (Madr). 2005, 33:285-7. 10.1157\/13080933","journal-title":"Allergol Immunopathol (Madr)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1159\/000513469","article-title":"Severe generalized bullous fixed drug eruption treated with cyclosporine: a case report and literature review","volume":"13","author":"Barootes HC","year":"2021","unstructured":"Barootes HC, Peebles ER, Matsui D, Rieder M, Abuzgaia A, Mohammed JA. Severe generalized bullous fixed drug eruption treated with cyclosporine: a case report and literature review. Case Rep Dermatol. 2021, 13:154-63. 10.1159\/000513469","journal-title":"Case Rep Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/451269-nimesulide-associated-generalized-bullous-fixed-drug-eruption-a-rare-pharmacovigilance-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:41:03Z","timestamp":1768236063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/451269-nimesulide-associated-generalized-bullous-fixed-drug-eruption-a-rare-pharmacovigilance-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.101371","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,12]]}}}